Photocure: First trial demonstrating reduced recurrence after flexible Blue Light Cystoscopy with Hexvix[®] in surveillance
Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. Randomized controlled multi-center study with 699 bladder cancer patients presented at Danish Urological Society meeting.Oslo, Norway November 18, 2019, Photocure ASA (PHO:OSE), is pleased to announce that results from new studies with flexible Blue Light Cystoscopy (BLC™) with Hexvix were presented at the annual meeting of the Danish Urology Society on Saturday, November 16. Results from a randomized controlled study in 699 patients from